Why the sudden excitement in CD3 T cell engagers? Follow the data…

Promising efficacy with early hints of durability. Lack of GR 3/4 CRS due to steroid co-administration - underscored by tarlatamab and HPN328 using fully active CD3. $JANX, $HARP, $CNTX

Congrats to TORL on their $158M Series B to fund their #CLDN6 ADC.

Context presented benchmarking data at SITC2023 comparing CTIM-76 to TORL-1-23. Highlights from the poster demonstrate ADC utility may be limited to tumors w/ very high levels of CLDN6. #CNTX

$BNTX CarVac (fixed dosed post anti-CLDN6 CAR-T)

We probably see the limits of the fixed dose regimen here, I think they'd need to increase the dose past 30 days, or maybe a bit later, but smthg like that.

📣 #SITC2023 Claudin 6 (CLDN6)

📆 $CNTX presents CTIM-76 benchmarking data
✅ 100x more potent than TORL-1-23
✅ 10x more potent than AMG-794
👍 Complete tumor regressions in ovarian cancer xenograft

#ESMO23 #Claudin6 ( #CLDN6 )
📣 Takeaways
⬆️ BNT211 active in multiple solid tumors
✅ BNT211 solid tolerability
⬇️ TORL-1-23 active only in CLDN6 high ovarian
☢️ TORL-1-23 dose being pushed very high to see broader activity

$CNTX #CTIM76

#ESMO23 #CLDN6
📣 BNT211 Ph 1 (n=44)
Dr John Haanen The Netherlands Cancer Institute
✅ ORR 44% in Ph 1a
✅ ORR 59% in DL2
✅ ORR 77% in ovarian at DL2
😁 3 PR in novel CLDN6 cancers
✅ CRS and ICANS moderate

BioNTech, pls let us know more about the 3 novel responders 🙏

OncoAlert, ESMO - Eur. Oncology

#ESMO23 #ovarian #ADC
📣 TORL-1-23 Ph 1 (n=42)
Dr Gottfried Konecny .
✅ ORR 31% (overall)
✅ ORR 50% at 3 mg/kg+
☢️ MMAE tox at 3 mg/kg+
♦️ No responses outside of CLDN6 high ovarian
➡️ lack of responses driving need to aggressively dose escalate?
OncoAlert ESMO - Eur. Oncology

#ESMO2023
—> BioNTech BNT211 targeting Claudin 6 (CLDN6) late-breaker (LBA35).

+19 pts from ASCO2023

42% ORR at DL2+

CarVAC enhancing T cell persistence

$CNTX

#ESMO2023 , TORL-1-23 limited update in abstract from #ASCO2023 .

5 new patients, all ovarian and testicular. 1 incremental PR, so overall response rates holding firm.

BNT211 patient population is more diverse.

⁦ #ESMO2023 : Claudin 6 (CLDN6) Late-Breaker for BioNTech BNT211 cell therapy.

At ASCO2023, we learned of a response in “other” cancer outside of ovarian and testicular. Will BNT211 be the first CLDN6 asset to establish PoC in 3 tumor types?

Looking forward to two Claudin6 x CD3 bispecific presentations at #SITC2023 .

Chugai/Roche to present first public data on SAIL66.

Context ($CNTX) to present preclinical update on CTIM-76.

These presentations follow TORL BioTherapeutics Ph 1 update at #ESMO2023 .

We are pleased to announce that an abstract regarding Context’s #preclinical candidate, CTIM-76, a CLDN6 x CD3 bispecific antibody, targeting CLDN6 positive #cancers has been selected for poster presentation at the Society for Immunotherapy of Cancer Annual Meeting. $CNTX #SITC23 ir.contexttherapeutics.com/news-releases/…

Looking forward to upcoming #CLDN6 clinical updates from TORL (October) and BioNTech (2H23). Perhaps first glimpse of clinical activity in NSCLC?

#Claudin , $CNTX

New data from Context Therapeutics comparing expression of Claudin 6 (CLDN6) versus top lung and ovarian cancer targets.

Low correlation with TROP2 and Nectin-4, and no correlation with EGFR in lung.

No correlation with FRa in ovarian.

Potentially distinct target population for CLDN6.

#ASCO23 provided many exciting advancements to treat #cancer including #clinicalresearch updates from novel therapies targeting Claudin 6 (CLDN6) to potentially treat #ovariancancer . Read more about this promising #data . $CNTX benzinga.com/general/biotec…

BioNTech BNT211 #CLDN6 CAR-T update at #ASCO2023 highlights:

75% ORR at DL2

80% ORR (4/5 pts) at DL2 in late-line ovarian cancer

Clinical validation with BNT211 now achieved in late-line ovarian and testicular (57% ORR disclosed at #ESMO2022 ) cancer. $CNTX

TORL Claudin 6 data did not disappoint.

32% ORR across all doses in Ph 1 dose escalation in ovarian cancer.

75% ORR (n=4) at highest dose (2.4mg/kg) in ovarian cancer.

Lots more to come from Claudin 6 at #ASCO2023 . $CNTX, BioNTech prnewswire.com/news-releases/…

$263 million raised for early-stage #Claudin programs from Alentis Therapeutics and TORL BioTherapeutics.

Great investor syndicates including Perceptive, Deep Track, RA, Schroeders, Jeito, BMS, Novo

#ICYMI , $CNTX

Congrats to TORL BioTherapeutics on their $158M Series B to fund Claudin 6 ADC.

Claudin 6 is enriched in lung, testicular, and ovarian cancers.

#Claudin , #CLDN6 , $CNTX

prnewswire.com/news-releases/…

Excited to announce today:

development candidate for 2nd program

CTIM-76 is a Claudin 6 x CD3 bispecific antibody

Press release: ir.contexttherapeutics.com/news-releases/…

Data: ir.contexttherapeutics.com/static-files/4…

$CNTX